Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs.
Vaccine
; 13(1): 72-6, 1995 Jan.
Article
em En
| MEDLINE
| ID: mdl-7762282
ABSTRACT
Imiquimod, an immunomodulator which upregulates cell-mediated immune responses, was evaluated as an adjuvant for immunotherapy of recurrent genital herpes simplex virus (HSV) infection in guinea-pigs. In two experiments at separate research centres, animals were immunized with HSV glycoprotein and either placebo, 1 or 5 days of imiquimod, or complete Freund's adjuvant, 14 and 35 days after genital HSV-2 infection. Recurrent lesion days were then evaluated from days 15-91. In both experiments, immunization with glycoprotein and imiquimod most effectively reduced recurrence compared with unimmunized controls (53-69%, p < 0.001-0.05). A peak reduction of 70-80% was observed following the second immunization. This reduction was greater than that provided by immunization with glycoprotein and complete Freund's adjuvant in these experiments or those previously reported.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Glicoproteínas
/
Herpes Genital
/
Proteínas do Envelope Viral
/
Adjuvantes Imunológicos
/
Aminoquinolinas
/
Imunoterapia
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article